Genprex, Inc. (GNPX)
- Previous Close
2.1200 - Open
2.1700 - Bid --
- Ask --
- Day's Range
2.1000 - 2.3292 - 52 Week Range
2.0900 - 42.4000 - Volume
23,115 - Avg. Volume
88,740 - Market Cap (intraday)
4.222M - Beta (5Y Monthly) -0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-22.5600 - Earnings Date May 22, 2024 - May 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
165.00
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
www.genprex.comRecent News: GNPX
Performance Overview: GNPX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNPX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNPX
Valuation Measures
Market Cap
4.22M
Enterprise Value
-2.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-108.64%
Return on Equity (ttm)
-207.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.86M
Diluted EPS (ttm)
-22.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
6.74M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.9M